Kevin Charles Francis Fone

Prof. Kevin Charles Francis Fone

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
KFKevin Charles Francis Fone
Kevin Charles Francis Fone
MPM. Veronica Porkess
M. Veronica Porkess

1 May 2014 in European Neuropsychopharmacology
Verified
Journal Article
Open access
MMMark J. Millan
Mark J. Millan
KFKevin Charles Francis Fone
Kevin Charles Francis Fone
TSThomas Steckler
Thomas Steckler
WHWilliam P. Horan
William P. Horan
Schizophrenia is a complex and multifactorial disorder generally diagnosed in young adults at the time of the first psychotic episode of delusions and hallucinations. These positive symptoms can be controlled in most patients by currently-available antipsychotics. Conversely, they are poorly effective against concomitant neurocognitive dysfunction, deficits in social cognition and negative symptoms (NS), which strongly contribute to poor functional outcome. The precise notion of NS has evolved over the past century, with recent studies - underpinned by novel rating methods - suggesting two major sub-domains: "decreased emotional expression", incorporating blunted affect and poverty of speech, and "avolition", which embraces amotivation, asociality and "anhedonia" (inability to anticipate pleasure). Recent studies implicate a dysfunction of frontocortico-temporal networks in the aetiology of NS, together with a disruption of cortico-striatal circuits, though other structures are also involved, like the insular and parietal cortices, amygdala and thalamus. At the cellular level, a disruption of GABAergic-glutamatergic balance, dopaminergic signalling and, possibly, oxytocinergic and cannibinoidergic transmission may be involved. Several agents are currently under clinical investigation for the potentially improved control of NS, including oxytocin itself, N-Methyl-d-Aspartate receptor modulators and minocycline. Further, magnetic-electrical "stimulation" strategies to recruit cortical circuits and "cognitive-behavioural-psychosocial" therapies likewise hold promise. To acquire novel insights into the causes and treatment of NS, experimental study is crucial, and opportunities are emerging for improved genetic, pharmacological and developmental modelling, together with more refined readouts related to deficits in reward, sociality and "expression". The present article comprises an integrative overview of the above issues as a platform for this Special Issue of European Neuropsychopharmacology in which five clinical and five preclinical articles treat individual themes in greater detail. This Volume provides, then, a framework for progress in the understanding - and ultimately control - of the debilitating NS of schizophrenia.

1 January 2000 in Neuropharmacology
Verified
Journal Article
Closed access
DCDelyth A Clemett
Delyth A Clemett
TPTaniya Punhani
Taniya Punhani
MDMark S. Duxon
Mark S. Duxon
TBThomas P Blackburn
Thomas P Blackburn
KFKevin Charles Francis Fone
Kevin Charles Francis Fone

13 August 2008 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
LBLynn Bedford
Lynn Bedford
DHDavid Hay
David Hay
DADevoy Anny
Devoy Anny
SPSimon Paine
Simon Paine
DPDes G. Powe
Des G. Powe
RMR. John Mayer
R. John Mayer
Ubiquitin-positive intraneuronal inclusions are a consistent feature of the major human neurodegenerative diseases, suggesting that dysfunction of the ubiquitin proteasome system is central to disease etiology. Research using inhibitors of the 20S proteasome to model Parkinson's disease is controversial. We report for the first time that specifically 26S proteasomal dysfunction is sufficient to trigger neurodegenerative disease. Here, we describe novel conditional genetic mouse models using the Cre/loxP system to spatially restrict inactivation ofPsmc1(Rpt2/S4) to neurons of either the substantia nigra or forebrain (e.g., cortex, hippocampus, and striatum). PSMC1 is an essential subunit of the 26S proteasome andPsmc1conditional knock-out mice display 26S proteasome depletion in targeted neurons, in which the 20S proteasome is not affected. Impairment of specifically ubiquitin-mediated protein degradation caused intraneuronal Lewy-like inclusions and extensive neurodegeneration in the nigrostriatal pathway and forebrain regions. Ubiquitin and α-synuclein neuropathology was evident, similar to human Lewy bodies, but interestingly, inclusion bodies contained mitochondria. We support this observation by demonstrating mitochondria in an early form of Lewy body (pale body) from Parkinson's disease patients. The results directly confirm that 26S dysfunction in neurons is involved in the pathology of neurodegenerative disease. The model demonstrates that 26S proteasomes are necessary for normal neuronal homeostasis and that 20S proteasome activity is insufficient for neuronal survival. Finally, we are providing the first reproducible genetic platform for identifying new therapeutic targets to slow or prevent neurodegeneration.

1 September 2008 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
MKMadeleine Victoria King
Madeleine Victoria King
CMC Marsden
C Marsden
KFKevin Charles Francis Fone
Kevin Charles Francis Fone

1 February 2004 in Current Drug Targets-CNS & Neurological Disorders
Verified
Journal Article
Closed access
PDF file
MWMarie L Woolley
Marie L Woolley
CMCharles Marsden
Charles Marsden
KFKevin Charles Francis Fone
Kevin Charles Francis Fone
The 5-hydroxytryptamine6 (5-ht6) was one of the most recent additions to the5-HT receptor family, selective antagonists have recently been developed and potentialfunctional roles are now becoming apparent. The high affinity of a wide range ofpsychiatric drugs for the 5-ht6 receptor, together with its almost exclusive expression inthe CNS, being abundant in limbic and cortical regions, has stimulated significantresearch interest. The 5-ht6 receptor appears to regulate glutamatergic and cholinergicneuronal activity, and increasing evidence suggests that it may be involved in the regulationof cognition, feeding and, possibly, affective state and seizures. The current article will review all aspectsof the discovery, genetics, distribution, pharmacology and function of the 5-ht6 receptor. Taken together, thiswealth of information warrants the use of the upper case nomenclature for the 5-ht6 receptor to be approved andits true status recognised.